Company intelligence / Profile preview

Relypsa, Inc.

Redwood City, California, United Statespitchbook.com ↗

Ownership: Private
Employees: ~67
Development stage: Commercial

Overview

Relypsa developed non-systemic polymer-based drugs targeting renal and cardiovascular conditions. Its lead product candidate patiromer for oral suspension (Veltassa®) received FDA approval for the treatment of hyperkalemia. The company had global royalty-free commercialization rights to this drug with US intellectual property protection until at least 2030. Clinical results demonstrated efficacy in lowering serum potassium in patients with chronic kidney disease or heart failure on RAAS inhibitors.

Therapeutic areas: CardiovascularMetabolic DisordersNephrology
Modalities: Non-absorbed polymeric drugs
Industry: Biotech

Drug pipeline

1 asset

patiromer

Commercial

Indications: Hyperkalemia

Beyond the preview

Go deeper on Relypsa, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Relypsa, Inc..

Explore the full profile